{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:44:08Z","timestamp":1789055048683,"version":"build-2803163510"},"reference-count":80,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Calliditas Therapeutics"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/1744666x.2023.2206119","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T15:15:04Z","timestamp":1682608504000},"page":"699-710","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":26,"title":["Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy"],"prefix":"10.1080","volume":"19","author":[{"given":"Jonathan","family":"Barratt","sequence":"first","affiliation":[{"name":"College of Medicine Biological Sciences and Psychology, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Lafayette","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Stanford University, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H","family":"Rovin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Fellstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2018.05.013"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq665"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1206793"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx189"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00837.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00884-7"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1159\/000225563"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90300-3"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74475"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1159\/000481636"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018101017"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3699-z"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/iji.12561"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.501"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801238-3.65665-9"},{"issue":"9","key":"cit0016","first-page":"716","volume":"58","author":"Cornes JS","year":"1965","journal-title":"Proc R Soc Med"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.07.006"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.08.009"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/823710"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200205000-00004"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601775"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm346"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03616.x"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70141-1"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/BF00853592"},{"issue":"1","key":"cit0026","first-page":"33","volume":"68","author":"Leinikki PO","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa264"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694787"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006060658"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.060003969.x"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3118"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2007.10.004"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016060640"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112493"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000716"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.05.017"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.01.1073"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2022.58.1.3352743"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.572754"},{"key":"cit0044","unstructured":"ClinicalTrials.gov. Clinical trial to assess efficacy and safety of the human anti-CD38 antibody felzartamab (MOR202) in IgA nephropathy (IGNAZ). 2022. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05065970 [accessed Mar 3, 2023]"},{"key":"cit0045","unstructured":"ClinicalTrials.gov. A study of mezagitamab in adults with primary immunoglobulin A nephropathy receiving stable background therapy. 2022. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05174221 [accessed Mar 3, 2023]"},{"key":"cit0046","unstructured":"ClinicalTrials.gov. Safety and efficacy of AT-1501 in patients with IgA nephropathy (IgAN). 2022. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05125068 [accessed Mar 3, 2023]"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.08.003"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab294"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712572"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac296"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.106895"},{"key":"cit0052","unstructured":"Chemical entities of biological interest. CHEBI: 3207 - budesonide. 2019. Available at: https:\/\/www.ebi.ac.uk\/chebi\/searchId.do?chebiId=CHEBI:3207 [accessed Mar 3, 2023]"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr052"},{"key":"cit0054","first-page":"388. TH","volume":"30","author":"Jerling M","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"cit0055","first-page":"121","volume":"4","author":"Bhachu JS","year":"2018","journal-title":"Kidney Dis"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa142.P0344"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020081208"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30550-0"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000068460.37369.DC"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.499"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.23"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.02.042"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08600718"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30314-0"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019010007"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.06.009"},{"key":"cit0067","unstructured":"ClinicalTrials.gov. Efficacy and safety of Nefecon in patients with primary IgA (immunoglobulin A) nephropathy (NefIgArd). 2021. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03643965 [accessed Mar 3, 2023]"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.09.017"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050526"},{"key":"cit0070","unstructured":"STADA Arzneimittel AG. Kinpeygo (budesonide) European Summary of Product Characteristics. Bad Vilbel: Germany; 2022 [accessed Mar 3, 2023] Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/kinpeygo-epar-product-information_en.pdf"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019010009"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9362"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463"},{"key":"cit0074","unstructured":"Calliditas Therapeutics AB. Tarpeyo (budesonide) US Prescribing Information. Stockholm: Sweden; Dec 2021 [accessed Mar 3, 2023] Available from: https:\/\/www.tarpeyohcp.com\/prescribinginformation.pdf"},{"key":"cit0075","unstructured":"Calliditas Therapeutics AB. FDA grants Calliditas Therapeutics accelerated approval of TARPEYO\u2122 (budesonide) to reduce proteinuria in IgA nephropathy. 2021. Available at: https:\/\/www.calliditas.se\/en\/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide-to-reduce-proteinuria-in-iga-nephropathy\/ [accessed Mar 3, 2023]"},{"key":"cit0076","unstructured":"PR Newswire. European Commission approves Kinpeygo\u00ae for adults with primary IgA nephropathy. 2022. Available at: https:\/\/www.prnewswire.com\/news-releases\/european-commission-approves-kinpeygo-for-adults-with-primary-iga-nephropathy-301587501.html [accessed Mar 3, 2023]"},{"key":"cit0077","unstructured":"ClinicalTrials.gov. Efficacy and safety in patients with primary IgA nephropathy who have completed study Nef-301 (Nefigard-OLE). 2023. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04541043 [accessed Mar 3, 2023]"},{"key":"cit0078","unstructured":"The Pharma Letter. British medicines regulator grants three new marketing authorizations. 2023. Available at: https:\/\/www.thepharmaletter.com\/article\/british-medicines-regulator-grants-two-new-marketing-authorizations [accessed Mar 3, 2023]"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac107.001"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac107.002"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2023.2206119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T07:43:08Z","timestamp":1688542988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2023.2206119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/1744666X.2023.2206119"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2023.2206119","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}